uniQure Presents Late-Breaking Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B at the 62 nd Annual Meeting of the American Society of Hematology ~ First primary

Presents Late-Breaking Data from the HOPE-B Pivotal Trial of

Dezaparvovec Gene Therapy in Patients with Hemophilia B at the

Annual Meeting of the American Society of Hematology

endpoint in study met with mean Factor IX activity of 37% of normal at 26 weeks ~

91% reduction in reported bleeds requiring treatment, with 87% of patients

no such bleeds during the 26 weeks after dosing ~

increases in Factor IX activity maintained for up to 18 months

of pre-existing neutralizing antibodies ~

Etranacogene dezaparvovec was well-tolerated with no treatment-related serious adverse events ~

to host investor webcast today at 5:00 p.m. ET ~

MA and Amsterdam, the Netherlands, December 8, 2020 - uniQure N.V. (NASDAQ:

QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced

the late-breaking presentation of initial data from its pivotal, Phase III HOPE-B gene therapy trial of etranacogene

dezaparvovec, an investigational adeno-associated virus five (AAV5)-based

gene therapy for the treatment of patients with severe and moderately severe hemophilia B. This is the first data set to be reported

from a Phase III gene therapy study in hemophilia B and, with 54 patients, the largest set of patients receiving a single gene

therapy investigational product to be reported to date. These clinical data will be presented today in an oral session at the

virtual 62nd Annual Meeting of the American Society of Hematology (ASH). The oral presentation slides are available

in the Investors section of uniQure's website under Investor Downloads.

"These initial data on etranacogene

dezaparvovec are encouraging, because thus far in these patients, severe hemophilia B appears to have been transformed into a functionally

curative state following administration of this one-time gene therapy, providing cessation in bleeding for a majority of patients

and no need for ongoing, chronic replacement therapy," stated Steven Pipe, M.D., professor of pediatrics and pathology and

pediatric medical director of the hemophilia and coagulation disorders program at the University of Michigan, and the principal

investigator of the HOPE-B pivotal trial.

"Importantly, these data also show

that those patients in the trial who may not have been eligible for other gene therapies because they had pre-existing neutralizing

antibodies (NAbs) have achieved results with etranacogene dezaparvovec that are comparable to the results of patients who did not

have pre-existing NAbs," he added. "This is an important distinction as this is the only known clinical trial that

has maximized patient eligibility in this way. The initial data also show that etranacogene dezaparvovec has been generally well

Patients in the Phase III HOPE-B clinical

study were initially enrolled into a prospective, observational lead-in period of at least six months during which bleeding events

and FIX replacement therapy usage were monitored. All patients required prophylactic routine FIX replacement prior to entering

the clinical trial, and patients were not excluded from the trial based on pre-existing NAbs to AAV5. The primary endpoints in

the study include FIX activity at 26-weeks and 52-weeks after dosing and annualized bleeding during the 52 weeks after dosing.

More than 80 percent of the 54 patients

treated in the open-label study had severe hemophilia with endogenous FIX activity at 1%. Forty-three percent of patients in

the study had NAbs to AAV5 up to a maximum titer of over 3,200. Fifty-four patients reported 123 bleeds during the lead-in phase

of the study, even while they remained on prophylactic replacement therapy.

Key Initial Efficacy Findings From HOPE-B

Key Initial Safety Findings From HOPE-B

Investor Webcast Information

management along with Dr. Pipe will host an investor webcast on Tuesday, December 8, 2020, at 5:00 p.m. ET. To access the live

webcast with presentation slides, please visit the Investor Relations section of uniQure's website at www.uniQure.com.

The webcast will be archived for 90 days. The event also may be accessed by dialing (877) 870-9135 for domestic callers

and +44 020 719 283 38 for international callers. The passcode is 3164585. Please specify to the operator that you would like

to join the "uniQure Conference Call."

About Etranacogene Dezaparvovec

Etranacogene dezaparvovec consists of an

AAV5 viral vector carrying a gene cassette with the patent-protected Padua variant of Factor IX (FIX-Padua). uniQure holds multiple

issued patents in the United States and Canada broadly covering methods of treating bleeding disorders, including hemophilia B,

using AAV gene therapy with the FIX-Padua variant. Etranacogene dezaparvovec has been granted Breakthrough Therapy Designation

by the United States Food and Drug Administration and access to Priority Medicine (PRIME) regulatory initiative by the European

Medicines Agency. In June 2020, the Company and CSL Behring entered into a licensing agreement providing CSL Behring with exclusive

global rights to etranacogene dezaparvovec. This licensing agreement is subject to antitrust regulatory review in the United States,

Australia and the United Kingdom that is currently ongoing.

AAV5-based gene therapies have been demonstrated

to be safe and well tolerated in a multitude of clinical trials, including being well-tolerated to date in five uniQure trials

conducted in nearly 80 patients in hemophilia B and other indications. No patient treated in clinical trials with the uniQure's

AAV5 gene therapies has experienced any confirmed cytotoxic T-cell-mediated immune response to the capsid. Additionally, pre-clinical

and clinical data show that AAV5-based gene therapies may be viable treatments in patients with pre-existing antibodies to AAV5,

thereby potentially increasing patient eligibility for treatment compared to other gene therapy product candidates.

uniQure is delivering on the promise of

gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology

platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's

disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com

uniQure Forward-Looking Statements

This press release contains forward-looking

statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by

terms such as "anticipate," "believe," "could," "estimate," "expect," "goal,"

"intend," "look forward to", "may," "plan," "potential," "predict,"

"project," "should," "will," "would" and similar expressions. Forward-looking statements

are based on management's beliefs and assumptions and on information available to management only as of the date of this press

release. These forward-looking statements include, but are not limited to, whether clinical data from the HOPE-B Phase III pivotal

trial will be included in regulatory submissions to the FDA and EMA in the second half of 2021 or ever, whether the clinical data

proves to be meaningful for the long-term outlook for hemophilia gene therapy or etranacogene dezaparvovec, whether etranacogene

dezaparvovec has the potential to lead to increases in FIX activity in the normal range and provide well-tolerated, long-term clinical

benefits, whether AAV5-based gene therapies can provide clinical benefit to patients with pre-existing neutralizing antibodies,

and whether we will obtain regulatory approval of our agreement with CSL Behring or otherwise close the transaction. Our actual

results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without

limitation, risks associated with our and our collaborators' clinical development activities, clinical results, collaboration

arrangements, corporate reorganizations and strategic shifts, regulatory oversight, product commercialization and intellectual

property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in

uniQure's Quarterly Report on Form 10-Q filed on October 27, 2020. Given these risks, uncertainties and other factors, you

should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking

statements, even if new information becomes available in the future.